


# USE OF SIMPLIFIED HCV TESTING, DIAGNOSIS AND GENERIC SOFOSBUVIR/VELPATASVIR SUCCESSFUL TREATMENT OUTCOMES IN MYANMAR



Thaung YM, Aung NM, Chasela C, Chew KW, Barnard T, Cavanaugh C, Kelly R, Lwin AA, Sein YY, Marange F, van der Horst C, Xulu T, Thwin HT, Sanne I and Kyi KP



## Epidemiology and Overarching Challenges in Myanmar



## Purpose

To evaluate cost and treatment outcome of a simplified HCV testing, treatment and care model integrated with HIV testing and treatment among key affected population with HCV infection with or without HIV co-infection.

[www.EquipHealth.org](http://www.EquipHealth.org)

## Project Overview

**Target Population:** People Who Inject Drugs (PWID); Female Sex Workers (FSW); Men having Sex with Men (MSM).

**Project sample size:** Participants enrolled in 3 sites, linked to available laboratory testing facilities

**Treatment Regimen:** The treatment regimen is fixed-dose combination of sofosbuvir 400 mg/velpatasvir 100 mg (SOF/VEL) orally once daily for 12 weeks with or without weight-based ribavirin.

**Harm reduction:** All positives were referred to harm reduction services

**Treatment Evaluation:** HCV viral load (VL) using Roche or Gene Xpert was undertaken at baseline and week 24 (12 weeks after completion of treatment)


**Implementation sites:** Yangon, Mandalay and Kachin

**Project Duration:** June 2017 – September 2018

**Outcomes :** SVR 12, Cost outcomes


[www.EquipHealth.org](http://www.EquipHealth.org)

## Organizational structure of the EQUIP HCV Demonstration project in Myanmar




[www.EquipHealth.org](http://www.EquipHealth.org)

## Results



[www.EquipHealth.org](http://www.EquipHealth.org)

# Initial VL & SVR Results



## EQUIP: Hepatitis C Project



# Disclaimer

*USAID EQUIP Grant No. AID-OAA-A-1500070),  
no pharmaceutical industry funds.*



[www.EquipHealth.org](http://www.EquipHealth.org)